2seventy bio, Inc. (TSVT)
| Market Cap | 245.97M |
| Revenue (ttm) | 71.20M |
| Net Income (ttm) | -223.22M |
| Shares Out | 51.41M |
| EPS (ttm) | -4.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 194,113 |
| Open | 4.990 |
| Previous Close | 5.000 |
| Day's Range | 4.700 - 5.030 |
| 52-Week Range | 1.535 - 12.690 |
| Beta | 1.87 |
| Analysts | Buy |
| Price Target | 10.67 (+122.29%) |
| Earnings Date | May 8, 2024 |
About TSVT
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. [Read more]
Financial Performance
In 2023, 2seventy bio's revenue was $100.39 million, an increase of 9.72% compared to the previous year's $91.50 million. Losses were -$217.57 million, -14.39% less than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TSVT stock is "Buy." The 12-month stock price forecast is $10.67, which is an increase of 122.29% from the latest price.
News
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024. “In the first quarter of 2024, ...
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:0...
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms ...
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Offi...
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quar...
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webc...
2seventy bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will present at the following upcoming investor conferences: Guggenhei...
2seventy bio to sell experimental cell therapies to Regeneron
Cancer treatment maker 2seventy bio will sell all its experimental cell therapies to Regeneron Pharmaceuticals for an upfront payment of $5 million and focus on its sole approved product Abecma, the t...
2seventy bio Announces New Strategic Path Forward
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (ideca...
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December ...
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating it...
Engine Capital pushes for changes at cancer therapy developer 2seventy bio
Activist investor Engine Capital on Wednesday sent a letter to the board of cancer therapy developer 2seventy bio , urging a board refresh and the appointment of its chief operating officer Chip Baird...
Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value
NEW YORK--(BUSINESS WIRE)--Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (Nasdaq: TSVT) (“2seventy” or the “Company”) outstanding shares, today announced that it sent the belo...
Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug
Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for...
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment
Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential appro...
US FDA delays decision on Bristol Myers-2seventy bio cancer therapy
The U.S. Food and Drug Administration (FDA) will not make a decision on Bristol Myers Squibb and 2seventy bio's marketing application of their blood cancer therapy, Abecma, for earlier lines of treatm...
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the third quarter ended...
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 20...
2seventy bio to lay off 40% of workforce
2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma.
2seventy bio cutting 176 jobs, search for new chief executive
2seventy bio Inc. stock TSVT, -6.81% rose 2.7% in premarket trading on Tuesday after the T-cell drug company for cancer treatment said it's cutting 176 jobs or 40% of its work force and launching a se...
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a restructuring of its business operations and research and development model to significantly reduce costs while ...
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
CAMBRIDGE, Mass. & SHANGHAI, China--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative ...
2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will participate in a fireside...
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the second quarter ende...
2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023...